European Journal of Clinical and Biomedical Sciences

| Peer-Reviewed |

Analysis of Sputum Culture and Drug Sensitivity Test in Patients with Severe Pneumonia Who Have Abnormal Klebsiella Pneumoniae

Received: Apr. 20, 2020    Accepted: May 06, 2020    Published: May 19, 2020
Views:       Downloads:

Share This Article

Abstract

Objective: To analyze sputum culture and drug sensitivity test in patients with severe pneumonia who have abnormal Klebsiella pneumoniae. Methods: 216 patients who were diagnosed as severe pneumonia were invested to join our study. All participants received the sputum culture test before they receive the treatment, their inspection time was from January 2016 to December 2016. we use different antibiotic discs to test the drug resistance in test medium, it can test the effects of several major antibiotics on Klebsiella pneumoniae. Our research is focus on the information about Drug resistance for Klebsiella pneumoniae. The collection information includes patient characteristics, Klebsiella pneumoniae source medical department and drug resistance of different antibiotics for Klebsiella pneumoniae. Result: Most Klebsiella pneumoniae sample from ICU (29.6%), Respiratory ward (31.0%), Neurological ward (19.0%) and Cardiovascular ward (43.7%). The klebsiella pneumoniae sample of another source are less than 5% in our research result. Some antibiotics have good influence to Klebsiella pneumoniae, that include cefoperazone/sulbactam, Meropenem and Ciprofloxacin (8.9% & 10.9% & 12.9%). However, the result indicate the Aztreonam has strong drug resistance for Klebsiella pneumoniae, it has 66 out of 99 (66.66%) number of resistant. Conclusion: The cefoperazone/sulbactam, Meropenem and Ciprofloxacin have good influence to improve klebsiella pneumoniae situation on patients with severe pneumonia. Additionally, some medical departments have more patients who severe pneumonia caused by klebsiella pneumoniae, such as ICU, Respiratory ward, Neurological ward and Cardiovascular ward.

DOI 10.11648/j.ejcbs.20200602.12
Published in European Journal of Clinical and Biomedical Sciences ( Volume 6, Issue 2, April 2020 )
Page(s) 22-25
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Drug Resistance, Sputum Culture, Severe Pneumonia

References
[1] Teramoto S, Yoshida K, Hizawa N. Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. RespirInvestig. 2015; 53 (5): 178-84.
[2] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44: S27–72.
[3] Allewelt M, Schüler P, Bolcskei PL, Mauch H, Lode H. Pneumonia SGoA. Ampicillin sulbactam vs clindamycin/cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect. 2016; 10 (2): 163-170.
[4] Kadowaki M, Demura Y, Mizuno S, Uesaka D, Ameshima S, Miyamori I, et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest. 2015; 127 (4): 1276-1282.
[5] Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H, Group GLAS. Moxifloxacin vsampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection. 2018; 36 (1): 23-30.
[6] Barckow D, Schwigon CD. Cefepime versus cefotaxime in the treatment oflower respiratory tract infections. J Antimicrob Chemother. 1993; 32: 187-193.
[7] Kochanowski K, Morinishi L, Altschuler SJ, Wu LF. Drug persistence–from antibiotics to cancer therapies, Curr. Opin. Syst. Biol. 2018; 10: 1–8.
[8] Volm M, Efferth T. Prediction of cancer drug resistance and implications for personalized medicine, Front. Oncol. 2015; 5: 282.
[9] Nielsen BS, Balslev E, Poulsen TS, Nielsen D, Møller T, Mortensen CE, Holmstrøm K. miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer. Front. Oncol. 2016; 4: 207.
[10] Munoz-Price ls, Poirel l, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases, Lancet Infect. Dis. 2017; 13 (9): 785–796.
[11] Pitout JD, Nordmann P, Poirel L. Carbapenemase-Producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance, Antimicrob. Agents Chemother. 2015; 59 (10): 5873–5884.
[12] Navon-Venezia S, Kondratyeva K, Caratolli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Mic Rev. 2017; 41 (3): 252–75.
[13] Moradigaravand D, Martin V, Peacock SJ, Parkhill J. Evolution and epidemiology of multidrug-resistant Klebsiella pneumoniae in the United Kingdom and Ireland. mBio. 2017; 8 (1): 1976-1916.
[14] Montgomerie JZ. Epidemiology of Klebsiella and hospital-associated infections. Rev Infect Dis 1979; 1 (5): 736–53.
[15] Melot B, Colot J, Guerrier G. Bacteremic community-acquired infections due to Klebsiella pneumoniae: clinical and microbiological presentation in New Caledonia, 2008–2013. Int J Infect Dis 2015; 41: 29–31.
[16] Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the In- fectious Diseases Society of America and the Society for Healthcare Epidemi- ology of America. Clin Infect Dis 2016; 44: 51–77.
[17] Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic pre- scribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2016; 340: 2096.
[18] Baggs J, Fridkin SK, Pollack LA, Srinivasan A, Jernigan JA. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med 2016; 176: 1639–48.
[19] US Centers for Disease Control and Prevention. Antimicrobial Use and Resis- tance (AUR) Module. Atlanta, GA: CDC; 2017.
Cite This Article
  • APA Style

    Yanru Luo, Jufeng Li, Xuwei Lin, Lingfeng Zeng, Jieyi Zhou, et al. (2020). Analysis of Sputum Culture and Drug Sensitivity Test in Patients with Severe Pneumonia Who Have Abnormal Klebsiella Pneumoniae. European Journal of Clinical and Biomedical Sciences, 6(2), 22-25. https://doi.org/10.11648/j.ejcbs.20200602.12

    Copy | Download

    ACS Style

    Yanru Luo; Jufeng Li; Xuwei Lin; Lingfeng Zeng; Jieyi Zhou, et al. Analysis of Sputum Culture and Drug Sensitivity Test in Patients with Severe Pneumonia Who Have Abnormal Klebsiella Pneumoniae. Eur. J. Clin. Biomed. Sci. 2020, 6(2), 22-25. doi: 10.11648/j.ejcbs.20200602.12

    Copy | Download

    AMA Style

    Yanru Luo, Jufeng Li, Xuwei Lin, Lingfeng Zeng, Jieyi Zhou, et al. Analysis of Sputum Culture and Drug Sensitivity Test in Patients with Severe Pneumonia Who Have Abnormal Klebsiella Pneumoniae. Eur J Clin Biomed Sci. 2020;6(2):22-25. doi: 10.11648/j.ejcbs.20200602.12

    Copy | Download

  • @article{10.11648/j.ejcbs.20200602.12,
      author = {Yanru Luo and Jufeng Li and Xuwei Lin and Lingfeng Zeng and Jieyi Zhou and Zhidong Zhang},
      title = {Analysis of Sputum Culture and Drug Sensitivity Test in Patients with Severe Pneumonia Who Have Abnormal Klebsiella Pneumoniae},
      journal = {European Journal of Clinical and Biomedical Sciences},
      volume = {6},
      number = {2},
      pages = {22-25},
      doi = {10.11648/j.ejcbs.20200602.12},
      url = {https://doi.org/10.11648/j.ejcbs.20200602.12},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ejcbs.20200602.12},
      abstract = {Objective: To analyze sputum culture and drug sensitivity test in patients with severe pneumonia who have abnormal Klebsiella pneumoniae. Methods: 216 patients who were diagnosed as severe pneumonia were invested to join our study. All participants received the sputum culture test before they receive the treatment, their inspection time was from January 2016 to December 2016. we use different antibiotic discs to test the drug resistance in test medium, it can test the effects of several major antibiotics on Klebsiella pneumoniae. Our research is focus on the information about Drug resistance for Klebsiella pneumoniae. The collection information includes patient characteristics, Klebsiella pneumoniae source medical department and drug resistance of different antibiotics for Klebsiella pneumoniae. Result: Most Klebsiella pneumoniae sample from ICU (29.6%), Respiratory ward (31.0%), Neurological ward (19.0%) and Cardiovascular ward (43.7%). The klebsiella pneumoniae sample of another source are less than 5% in our research result. Some antibiotics have good influence to Klebsiella pneumoniae, that include cefoperazone/sulbactam, Meropenem and Ciprofloxacin (8.9% & 10.9% & 12.9%). However, the result indicate the Aztreonam has strong drug resistance for Klebsiella pneumoniae, it has 66 out of 99 (66.66%) number of resistant. Conclusion: The cefoperazone/sulbactam, Meropenem and Ciprofloxacin have good influence to improve klebsiella pneumoniae situation on patients with severe pneumonia. Additionally, some medical departments have more patients who severe pneumonia caused by klebsiella pneumoniae, such as ICU, Respiratory ward, Neurological ward and Cardiovascular ward.},
     year = {2020}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Analysis of Sputum Culture and Drug Sensitivity Test in Patients with Severe Pneumonia Who Have Abnormal Klebsiella Pneumoniae
    AU  - Yanru Luo
    AU  - Jufeng Li
    AU  - Xuwei Lin
    AU  - Lingfeng Zeng
    AU  - Jieyi Zhou
    AU  - Zhidong Zhang
    Y1  - 2020/05/19
    PY  - 2020
    N1  - https://doi.org/10.11648/j.ejcbs.20200602.12
    DO  - 10.11648/j.ejcbs.20200602.12
    T2  - European Journal of Clinical and Biomedical Sciences
    JF  - European Journal of Clinical and Biomedical Sciences
    JO  - European Journal of Clinical and Biomedical Sciences
    SP  - 22
    EP  - 25
    PB  - Science Publishing Group
    SN  - 2575-5005
    UR  - https://doi.org/10.11648/j.ejcbs.20200602.12
    AB  - Objective: To analyze sputum culture and drug sensitivity test in patients with severe pneumonia who have abnormal Klebsiella pneumoniae. Methods: 216 patients who were diagnosed as severe pneumonia were invested to join our study. All participants received the sputum culture test before they receive the treatment, their inspection time was from January 2016 to December 2016. we use different antibiotic discs to test the drug resistance in test medium, it can test the effects of several major antibiotics on Klebsiella pneumoniae. Our research is focus on the information about Drug resistance for Klebsiella pneumoniae. The collection information includes patient characteristics, Klebsiella pneumoniae source medical department and drug resistance of different antibiotics for Klebsiella pneumoniae. Result: Most Klebsiella pneumoniae sample from ICU (29.6%), Respiratory ward (31.0%), Neurological ward (19.0%) and Cardiovascular ward (43.7%). The klebsiella pneumoniae sample of another source are less than 5% in our research result. Some antibiotics have good influence to Klebsiella pneumoniae, that include cefoperazone/sulbactam, Meropenem and Ciprofloxacin (8.9% & 10.9% & 12.9%). However, the result indicate the Aztreonam has strong drug resistance for Klebsiella pneumoniae, it has 66 out of 99 (66.66%) number of resistant. Conclusion: The cefoperazone/sulbactam, Meropenem and Ciprofloxacin have good influence to improve klebsiella pneumoniae situation on patients with severe pneumonia. Additionally, some medical departments have more patients who severe pneumonia caused by klebsiella pneumoniae, such as ICU, Respiratory ward, Neurological ward and Cardiovascular ward.
    VL  - 6
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • ICU, Peking University Shenzhen Hospital, Shenzhen, China

  • Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Section